These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37286267)

  • 1. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study.
    Cortés-Hernández J; Marras Fernández-Cid C; Andreu Sánchez JL; Calvo Alén J; García-Aparicio AM; Díez Álvarez E; Hidalgo Bermejo FJ; Coronell C; Perna A; Ordi Ros J
    Reumatol Clin (Engl Ed); 2023; 19(6):312-318. PubMed ID: 37286267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
    von Kempis J; Duetsch S; Reuschling N; Villiger R; Villiger PM; Vallelian F; Schaer DJ; Mueller RB
    Swiss Med Wkly; 2019 Feb; 149():w20022. PubMed ID: 30852830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.
    Babini A; Cappuccio AM; Caprarulo C; Casado G; Eimon A; Figueredo H; García MA; Magri S; Mannucci P; Perez Rodriguez S; Pons-Estel BA; Velozo EJ; Iglesias-Rodriguez M; Streger G
    Lupus; 2020 Oct; 29(11):1385-1396. PubMed ID: 32791930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies.
    Collins CE; Cortes-Hernández J; Garcia MA; von Kempis J; Schwarting A; Touma Z; Kurtinecz M; Gairy K
    Rheumatol Ther; 2020 Dec; 7(4):949-965. PubMed ID: 33206344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids.
    Lee YJ; Ahn SM; Hong S; Oh JS; Lee CK; Yoo B; Kim YG
    Korean J Intern Med; 2024 Mar; 39(2):338-346. PubMed ID: 38031366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study.
    Hunnicutt JN; Fairburn-Beech J; Georgiou ME; Richards A; Gregan YI; Quasny H; Chauhan D
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36450407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study.
    Bell CF; Chung J; Rubin B
    Rheumatol Ther; 2023 Apr; 10(2):447-462. PubMed ID: 36652052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
    Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
    Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steroid-sparing effect of belimumab: results from a retrospective observational study of real-world data.
    Worley K; Milligan S; Rubin B
    Lupus Sci Med; 2023 Dec; 10(2):. PubMed ID: 38135455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.
    Collins CE; Dall'Era M; Kan H; Macahilig C; Molta C; Koscielny V; Chang DJ
    Lupus Sci Med; 2016; 3(1):e000118. PubMed ID: 26835146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.
    Escalera CR; Guisado ÁMZ; Mateo FJ; Bahamontes-Rosa N; Villanueva MJG
    Clin Rheumatol; 2022 Nov; 41(11):3373-3382. PubMed ID: 35871173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.
    Schwarting A; Schroeder JO; Alexander T; Schmalzing M; Fiehn C; Specker C; Perna A; Cholmakow-Bodechtel C; Koscielny VB; Carnarius H
    Rheumatol Ther; 2016 Dec; 3(2):271-290. PubMed ID: 27804088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
    Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients.
    Scheinberg M; de Melo FF; Bueno AN; Costa CM; de Azevedo Bahr ML; Reis ER
    Clin Rheumatol; 2016 Jul; 35(7):1719-23. PubMed ID: 27106543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.
    Ke X; Eisenberg Lawrence DF; Oglesby A; Patel J; Kan H; Boggs R
    Clin Ther; 2015 Dec; 37(12):2852-63. PubMed ID: 26547483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.